An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis

Meshkinpour, Azin; Sun, Joannie D; Weinstein, Gerald D.

doi:10.1067/mjd.2003.450

Cited by 54 publications

(31 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although seborrheic dermatitis fluctuates in severity, it can persist for several years and it may predispose to psoriasis [32] . Two open studies and several case reports suggest that TCIs are effective in the treatment of adult seborrhoeic dermatitis [23,[33][34][35][36][37] . In a study by Meshkinpour et al, the face, ears, and scalp of 18 patients were treated with tacrolimus ointment 0.1% twice daily for 4 weeks [36] .…”

Section: Seborrhoeic Dermatitismentioning

confidence: 99%

“…Two open studies and several case reports suggest that TCIs are effective in the treatment of adult seborrhoeic dermatitis [23,[33][34][35][36][37] . In a study by Meshkinpour et al, the face, ears, and scalp of 18 patients were treated with tacrolimus ointment 0.1% twice daily for 4 weeks [36] . Data from a 20-patient study by Rigopoulos and colleagues comparing pimecrolimus with betamethasone 17-valerate showed both treatments were effective for seborroeic dermatitis [37] .…”

Section: Seborrhoeic Dermatitismentioning

confidence: 99%

See 1 more Smart Citation

Potential New Indications of Topical Calcineurin Inhibitors

Luger

Paul

2007

Dermatology

View full text Add to dashboard Cite

The topical calcineurin inhibitors pimecrolimus (Elidel®) and tacrolimus (Protopic®) were initially developed for the treatment of atopic eczema (atopic dermatitis), a chronic or chronically relapsing skin condition most prevalent in infants and children. Their main advantages compared with conventional topical corticosteroid therapy are that they are more selective in their mode of action, do not induce skin atrophy and are not associated with significant systemic absorption. In addition, topical calcineurin inhibitors may represent a useful alternative to topical corticosteroids for the treatment of a number of other inflammatory skin diseases. Preferred sites for the use of topical calcineurin inhibitors are areas such as the face, neck, flexures, and genital areas, which are more susceptible to topical corticosteroid side effects. The efficacy of topical calcineurin inhibitors has been demonstrated for flexural psoriasis, seborrhoeic, contact and hand eczema. Preliminary data also support the efficacy of topical calcineurin inhibitors in lichen planus, facial lupus erythematosus, autoimmune bullous dermatosis, and vitiligo. In these latter indications, controlled studies are needed to better understand the efficacy and safety of topical calcineurin inhibitors and their role in disease management.

show abstract

Section: Seborrhoeic Dermatitismentioning

confidence: 99%

Section: Seborrhoeic Dermatitismentioning

confidence: 99%

Potential New Indications of Topical Calcineurin Inhibitors

Luger

Paul

2007

Dermatology

View full text Add to dashboard Cite

show abstract

“…[81][82][83] Application-site reactions are common during the first few days of treatment, but are generally transient and rarely result in treatment discontinuation. 81 Tacrolimus (0.1%) has also shown promising results in the treatment of moderate-to-severe seborrheic dermatitis, 84,85 contact dermatitis, 86 vulvar and anogenital lichen sclerosus, 87,88 rosacea, 89 cutaneous lupus erythematosus, 90,91 and bullous pemphigoid. 92,93 FIGURE 2 Calcineurin inhibitors disrupt the signal transduction pathway leading to T-cell activation.…”

Section: Tacrolimusmentioning

confidence: 98%

Mechanism of Action and Emerging Role of Immune Response Modifier Therapy in Dermatologic Conditions

Sauder

2004

J Cutan Med Surg

View full text Add to dashboard Cite

Immune response modifiers (IRMs) are agents that target the body's immune system (i.e., cytokines, receptors, and inflammatory cells) to combat disease. Topical IRM therapies, which encompass both proinflammatory and immunosuppressive therapeutics, have been used to successfully treat a number of dermatologic conditions. Proinflammatory treatments include Toll-like receptor agonists (e.g., imiquimod 5% cream) and interferon (e.g., interferon-alpha) therapies, which have been used in the treatment of external genital warts, basal cell carcinoma, and other dermatologic diseases. Immunosuppressive therapies include topical and intralesional corticosteroids, anti-tumor necrosis factor agents (e.g., infliximab and etanercept), and anti-CD4+ T-cell agents, including calcineurin inhibitors and mycophenolate. These agents have been used to treat a number of conditions, including atopic and seborrheic dermatitis and psoriasis. This article reviews the mechanism of action of IRMs and the application of IRMs in several dermatologic diseases.

show abstract

“…A pilot openlabel study treated 18 patients (16 patients with moderate-to-severe seborrheic dermatitis) with 0.1% tacrolimus twice daily for up to 28 days. 54 Eleven of the 18 patients had complete clearance of seborrheic dermatitis (i.e., grade 0 for global, erythema, and scaling severity scales). Six of these patients cleared by day 7 and 5 patients cleared by day 14.…”

Section: Seborrheic Dermatitismentioning

confidence: 99%

Role of Topical Therapies in the Management of Cutaneous Disease

Skinner

2004

J Cutan Med Surg

View full text Add to dashboard Cite

Within the last decade, healthcare providers have had a larger selection of effective novel topical immunomodulatory agents to treat many dermatologic conditions. Novel mechanisms of action of newer topical agents have facilitated differentiation from well-established topical agents such as corticosteroids and 5-fluorouracil. Further, because of a growing understanding of the immune mechanisms within the skin, the opportunity has arisen to use the body's immune system to effectively treat many dermatologic conditions, such as condyloma acuminata, actinic keratosis, basal cell carcinoma, and atopic dermatitis, while maintaining a favorable safety profile. Imiquimod 5% cream, an immune response modifier, is safe and effective in the treatment of condyloma acuminata, actinic keratosis, and primary superficial basal cell carcinoma (sBCC). Pimecrolimus cream 1% and tacrolimus ointment (0.1% and 0.03%) are safe and effective in the treatment of atopic dermatitis. This review highlights newer data on approved and investigational indications for these topical immunomodulatory agents.

show abstract

An open pilot study using tacrolimus ointment in the treatment of seborrheic dermatitis

Cited by 54 publications

References 17 publications

Potential New Indications of Topical Calcineurin Inhibitors

Potential New Indications of Topical Calcineurin Inhibitors

Mechanism of Action and Emerging Role of Immune Response Modifier Therapy in Dermatologic Conditions

Role of Topical Therapies in the Management of Cutaneous Disease

Contact Info

Product

Resources

About